^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Lung Adenocarcinoma
    Drug:everolimus (mTOR inhibitor) +
    ARS-1620 (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    IASLC-WCLC 2023
    Title:

    Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma

    Published date:
    08/08/2023
    Excerpt:
    We investigated the frequency of KARS G12C in resected 877 lung adenocarcinoma and 113 squamous cell carcinoma cases by ddPCR. The combination effect of KRAS inhibitor and mTOR inhibitor in lung KRAS G12C positive adenocarcinoma cell line (H23) and squamous cell carcinoma cell line (Calu-1)....We utilized three KRAS inhibitors (AMG-510, MRTX849, and ARS-1620) and mTOR inhibitor (Everolimus)....Combination index ranged 0.386-0.717 and 0.278-0.648 in MTS assay and Colony forming assay, respectively; in both cell lines, the combination of each KRAS inhibitor and Everolimus showed synergism. The cell growth was suppressed by dose-dependent manner...